Adaptimmune (ADAP) Presents Data on Liver Cancer Candidate

Published on September 6, 2021

Adaptimmune (ADAP) announces encouraging data from an early-stage study on liver cancer patients from its cell therapy candidate.

Continue reading on website
Other news

Can RH be Able to Retain Beat Streak This Earnings Season?

September 6, 2021
RH's fiscal Q2 results are likely to reflect its focus on online platforms, solid housing momentum and cost-saving initiatives despite persistent impa...

General Mills (GIS) Poised on Key Priorities, Costs Inflated

September 6, 2021
General Mills' (GIS) core priorities, focus on the Accelerate strategy and saving initiatives have been aiding the company amid an inflated cost scena...